drugset / Trial / NCT06672185
ARC101 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
Timeline
- Start
- 2025-02-05
- Primary completion
- 2028-05-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARC101 | Unknown | — | — |